Genetic mutations and aminoglycoside-induced ototoxicity in neonates

Romaine F. Johnson, Aliza P. Cohen, Yingshi Guo, Kurt Schibler, John H. Greinwald

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

OBJECTIVE: Mutations in the 12S rRNA gene have been associated with aminoglycoside-induced ototoxicity. Our objective was to study the relationship of these mutations in neonates, duration of aminoglycoside exposure, and other known risk factors to the presence of hearing loss. STUDY DESIGN: Prospective case-cohort study. SETTING: Three neonatal intensive care units (NICUs) in Cincinnati, OH. SUBJECTS AND METHODS: We studied a population of premature, low-birth-weight (< 2500 g) infants admitted to one of three ICUs. Demographic, genetic, clinical, and audiometric data were collected, and the prevalence of 12S rRNA mutations was calculated. RESULTS: Of the 436 patients enrolled in the study, 378 were exposed to gentamicin during their ICU stay. Mutations in the 12S rRNA gene were identified in four patients (0.9%), all of whom received gentamicin. Of the cohort, 256 patients (60%) received a complete audiometric assessment; 39 failed their initial hearing assessment. Only one of these patients had a 12S rRNA mutation. Of these 39 patients, the mean birth weight (1645 g vs 1306 g) was significantly less than the birth weight of those infants who passed their initial hearing screening. Definitive hearing assessment for those who failed showed no significant differences, however. CONCLUSION: The prevalence of 12S rRNA mutations related to aminoglycoside ototoxicity in our study population was approximately one percent. Most patients with this mutation and aminoglycoside exposure showed no evidence of hearing loss. Low birth weight was one risk factor related to the presence of failing a hearing assessment.

Original languageEnglish (US)
Pages (from-to)704-707
Number of pages4
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume142
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Aminoglycosides
Newborn Infant
Mutation
Hearing
Low Birth Weight Infant
Gentamicins
rRNA Genes
Hearing Loss
Birth Weight
Neonatal Intensive Care Units
Premature Birth
Population
Cohort Studies
Demography
ribosomal RNA 12S

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Genetic mutations and aminoglycoside-induced ototoxicity in neonates. / Johnson, Romaine F.; Cohen, Aliza P.; Guo, Yingshi; Schibler, Kurt; Greinwald, John H.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 142, No. 5, 05.2010, p. 704-707.

Research output: Contribution to journalArticle

Johnson, Romaine F. ; Cohen, Aliza P. ; Guo, Yingshi ; Schibler, Kurt ; Greinwald, John H. / Genetic mutations and aminoglycoside-induced ototoxicity in neonates. In: Otolaryngology - Head and Neck Surgery (United States). 2010 ; Vol. 142, No. 5. pp. 704-707.
@article{c5914d6c73624efb96279227c51642f2,
title = "Genetic mutations and aminoglycoside-induced ototoxicity in neonates",
abstract = "OBJECTIVE: Mutations in the 12S rRNA gene have been associated with aminoglycoside-induced ototoxicity. Our objective was to study the relationship of these mutations in neonates, duration of aminoglycoside exposure, and other known risk factors to the presence of hearing loss. STUDY DESIGN: Prospective case-cohort study. SETTING: Three neonatal intensive care units (NICUs) in Cincinnati, OH. SUBJECTS AND METHODS: We studied a population of premature, low-birth-weight (< 2500 g) infants admitted to one of three ICUs. Demographic, genetic, clinical, and audiometric data were collected, and the prevalence of 12S rRNA mutations was calculated. RESULTS: Of the 436 patients enrolled in the study, 378 were exposed to gentamicin during their ICU stay. Mutations in the 12S rRNA gene were identified in four patients (0.9{\%}), all of whom received gentamicin. Of the cohort, 256 patients (60{\%}) received a complete audiometric assessment; 39 failed their initial hearing assessment. Only one of these patients had a 12S rRNA mutation. Of these 39 patients, the mean birth weight (1645 g vs 1306 g) was significantly less than the birth weight of those infants who passed their initial hearing screening. Definitive hearing assessment for those who failed showed no significant differences, however. CONCLUSION: The prevalence of 12S rRNA mutations related to aminoglycoside ototoxicity in our study population was approximately one percent. Most patients with this mutation and aminoglycoside exposure showed no evidence of hearing loss. Low birth weight was one risk factor related to the presence of failing a hearing assessment.",
author = "Johnson, {Romaine F.} and Cohen, {Aliza P.} and Yingshi Guo and Kurt Schibler and Greinwald, {John H.}",
year = "2010",
month = "5",
doi = "10.1016/j.otohns.2010.01.030",
language = "English (US)",
volume = "142",
pages = "704--707",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Genetic mutations and aminoglycoside-induced ototoxicity in neonates

AU - Johnson, Romaine F.

AU - Cohen, Aliza P.

AU - Guo, Yingshi

AU - Schibler, Kurt

AU - Greinwald, John H.

PY - 2010/5

Y1 - 2010/5

N2 - OBJECTIVE: Mutations in the 12S rRNA gene have been associated with aminoglycoside-induced ototoxicity. Our objective was to study the relationship of these mutations in neonates, duration of aminoglycoside exposure, and other known risk factors to the presence of hearing loss. STUDY DESIGN: Prospective case-cohort study. SETTING: Three neonatal intensive care units (NICUs) in Cincinnati, OH. SUBJECTS AND METHODS: We studied a population of premature, low-birth-weight (< 2500 g) infants admitted to one of three ICUs. Demographic, genetic, clinical, and audiometric data were collected, and the prevalence of 12S rRNA mutations was calculated. RESULTS: Of the 436 patients enrolled in the study, 378 were exposed to gentamicin during their ICU stay. Mutations in the 12S rRNA gene were identified in four patients (0.9%), all of whom received gentamicin. Of the cohort, 256 patients (60%) received a complete audiometric assessment; 39 failed their initial hearing assessment. Only one of these patients had a 12S rRNA mutation. Of these 39 patients, the mean birth weight (1645 g vs 1306 g) was significantly less than the birth weight of those infants who passed their initial hearing screening. Definitive hearing assessment for those who failed showed no significant differences, however. CONCLUSION: The prevalence of 12S rRNA mutations related to aminoglycoside ototoxicity in our study population was approximately one percent. Most patients with this mutation and aminoglycoside exposure showed no evidence of hearing loss. Low birth weight was one risk factor related to the presence of failing a hearing assessment.

AB - OBJECTIVE: Mutations in the 12S rRNA gene have been associated with aminoglycoside-induced ototoxicity. Our objective was to study the relationship of these mutations in neonates, duration of aminoglycoside exposure, and other known risk factors to the presence of hearing loss. STUDY DESIGN: Prospective case-cohort study. SETTING: Three neonatal intensive care units (NICUs) in Cincinnati, OH. SUBJECTS AND METHODS: We studied a population of premature, low-birth-weight (< 2500 g) infants admitted to one of three ICUs. Demographic, genetic, clinical, and audiometric data were collected, and the prevalence of 12S rRNA mutations was calculated. RESULTS: Of the 436 patients enrolled in the study, 378 were exposed to gentamicin during their ICU stay. Mutations in the 12S rRNA gene were identified in four patients (0.9%), all of whom received gentamicin. Of the cohort, 256 patients (60%) received a complete audiometric assessment; 39 failed their initial hearing assessment. Only one of these patients had a 12S rRNA mutation. Of these 39 patients, the mean birth weight (1645 g vs 1306 g) was significantly less than the birth weight of those infants who passed their initial hearing screening. Definitive hearing assessment for those who failed showed no significant differences, however. CONCLUSION: The prevalence of 12S rRNA mutations related to aminoglycoside ototoxicity in our study population was approximately one percent. Most patients with this mutation and aminoglycoside exposure showed no evidence of hearing loss. Low birth weight was one risk factor related to the presence of failing a hearing assessment.

UR - http://www.scopus.com/inward/record.url?scp=77951922864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951922864&partnerID=8YFLogxK

U2 - 10.1016/j.otohns.2010.01.030

DO - 10.1016/j.otohns.2010.01.030

M3 - Article

C2 - 20416460

AN - SCOPUS:77951922864

VL - 142

SP - 704

EP - 707

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 5

ER -